Integrated Biopharma Inc (INBP)

Integrated Biopharma, Inc. is a common stock listing on OTC Markets for Integrated Biopharma Inc. The company, through its subsidiaries, is involved in the manufacturing, distribution, marketing, and sale of vitamins, nutritional supplements, and herbal products, with activities concentrated in the United States and Luxembourg. Its operations are organized into two segments: Contract Manufacturing, which produces vitamins and nutritional supplements for distributors, multilevel marketers, and specialized health-care providers; and Other Business Lines, which includes warehousing and fulfilment services as well as raw material distribution. Incorporated in 1980 and based in Hillside, New Jersey, the company was previously known as Integrated Health Technologies, Inc.


Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
OTC-INBP
$0.23
24.6% Upside
Undervalued
Not available
Not available
Good
0.0%
September 24, 2026
0.3x
0.1x
5.737 M
3.176 M
37.2%
23.2%
0.9
-171.6%
Valuation • Fair Value

Integrated Biopharma Inc (OTC-INBP) Fair Value by Valuation Model

Review the available estimates for Integrated Biopharma Inc (OTC-INBP), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$0.23

Estimated upside of 24.6% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$0.28

Discounted cash flow valuation reference.

Comps Fair Value

$0.21

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 4 available valuation references for Integrated Biopharma Inc (OTC-INBP) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Integrated Biopharma Inc (OTC-INBP)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

48.251 M

Current operating scale indicator.

Revenue Forecast

56.255 M

Forward revenue estimate.

EBITDA

-953 K

Current operating profitability reference.

EBITDA Forecast

1.497 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Integrated Biopharma Inc (OTC-INBP) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Integrated Biopharma Inc (OTC-INBP)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Good

Positive financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

-3.06

No elevated caution signal from this screen.

Altman Z-Score

0.9

Lower score that deserves closer risk review.

FCF / Net Income

-171.6%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Integrated Biopharma Inc (OTC-INBP). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Integrated Biopharma Inc (OTC-INBP)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

September 24, 2026

Days to Earnings

2

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Integrated Biopharma Inc (OTC-INBP), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Integrated Biopharma Inc (OTC-INBP) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Integrated Biopharma Inc (OTC-INBP) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Integrated Biopharma Inc (OTC-INBP) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Neutral

The weekly technical read for Integrated Biopharma Inc (OTC-INBP) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Integrated Biopharma Inc (OTC-INBP) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ Fast Investor Answers

Integrated Biopharma Inc (OTC-INBP) Stock FAQ

Data-supported answers about Integrated Biopharma Inc (OTC-INBP), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.23
Estimated upside 24.6%
Valuation Rating
Undervalued
Estimated upside of 24.6%
Financial Health
Good
Current financial-health read

The current fair value estimate for Integrated Biopharma Inc (OTC-INBP) is $0.23. This implies an estimated upside of 24.6% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 24.6% versus the current market price.

The current financial health read for Integrated Biopharma Inc (OTC-INBP) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Integrated Biopharma Inc (OTC-INBP) is September 24, 2026.

The latest available data indicates no current dividend yield for Integrated Biopharma Inc (OTC-INBP).

The current market capitalization listed for Integrated Biopharma Inc is 5.737 M.

The current enterprise value listed for Integrated Biopharma Inc is 3.176 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Integrated Biopharma Inc is OTC-INBP, and the stock is listed on OTC Markets.

Integrated Biopharma Inc (OTC-INBP) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Integrated Biopharma Inc is 37.2%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Integrated Biopharma Inc is 23.2%. Free float helps investors understand how much of the share base is available for public trading.